KR102472263B1 - An antimicrobial composition against oral bacteria, including sophoraflavanone g and rhein - Google Patents

Abstract

The present invention relates to an antibacterial composition for oral bacteria and a pharmaceutical composition for treatment of oral bacteria, including Sophoraflavanone G and Rhein.

Description

Antibacterial composition against oral bacteria containing sophoraflavanone G and rain

The present invention relates to an antibacterial composition for oral bacteria and a pharmaceutical composition for treatment of oral bacteria, including Sophoraflavanone G and Rhein.

S. mutans , S. sobrinus , A. viscosus , F. nucleatum, and P. gingivalis are the main causes of oral infection, and about 60% of adults suffer from dental caries and periodontal disease. These diseases in the oral cavity are usually infectious diseases caused by resident bacteria that form colonies on the tooth surface, gingiva or subgingival region, and it has been reported that more than 500 kinds of bacteria exist in the human oral cavity.

The most important factor in oral diseases represented by periodontal disease and dental caries is plaque composed of resident bacteria in the oral cavity. The main bacteria associated with periodontal disease and dental caries are mainly Gram-negative bacteria, which are involved in the initiation and progression of periodontal disease.

Meanwhile, it has recently been reported that not only oral diseases but also oral bacteria are associated with systemic diseases such as pneumonia and cardiovascular diseases. Recently, there is a demand for development of an oral therapeutic agent that solves these problems and can be safely used from the side effects of drugs.

Korean Patent Registration No. 10-1555214

An object of the present invention is to provide an antibacterial composition for oral bacteria comprising Sophoraflavanone G and Rhein.

Another object of the present invention is to provide a pharmaceutical composition for treating infections caused by oral bacilli, including sophoraflabanone G and lane.

Another object of the present invention is to provide an antibacterial adjuvant against oral bacteria comprising sophoraflavanone G and rain.

One aspect of the present invention is sophora flavanone G of Formula 1; And it relates to an antibacterial composition for oral bacteria comprising a lane of formula (2).

Sophoraflavanone G of Formula 1 is (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8--[(2R)-5-methyl-2-( Prof-1-en-2-yl)hex-4-en-pyradin-1-yl]-2,3-dihydro-4H-chromen-4-one (2S)-2-(2,4 -dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-2,3-dihydro It can be named as -4H-chromen-4-one.

The lane of Chemical Formula 2 may be named 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid.

In the present invention, 'Sophoraflavanone G' is a kind of volatile phytocides. The phytosides is an antibacterial organic compound extracted from plants, and is a substance that plays an important role in plant immunity and the relationship between organisms in the ecosystem, and also inhibits or kills the growth and development of bacteria, fungi and protozoa. Onions, garlic, horseradish, pine, oak, eucalyptus, and plants belonging to the genus Sophora produce phytosides. The range of antibacterial activity of the phytosides is largely divided depending on the species, and mainly affects protozoa, bacteria, fungi, and insects, but has little effect on animals in many cases.

The sophora flavanone G can be isolated from Sophora flavescens , Sophora pachycarpa or Sophora exigua .

Specifically, the sophoraflabanone G of Chemical Formula 1 may be isolated from Kosam.

In the present invention, 'gosam ( Sophora flavescens )' belongs to the leguminous dicotyledonous plant Rosaceae, and is a perennial herb that commonly grows in grasslands below 1000 m above sea level, and grows wild in mountains and fields throughout Korea. The roots are dug up in the fall, washed and dried, and are called gosam. The pharmacological effects such as anti-allergy, antiarrhythmia, antibacterial action, and diuretic action have been reported, and the gosam is used as a medicine for various diseases.

The main active ingredients of the gosam are matrin, oxymatrine, sophoraflavanone G, kurarinone, alkaloid, flavonoid and saponin ) contains.

The high ginseng may be extracted using low-temperature water of less than 40 ° C. or high-temperature water of 60 ° C. or more as a solvent, or may be extracted using alcohol as a solvent. The alcohol may be an aliphatic alcohol having 1 to 6 carbon atoms, and specifically, methanol, ethanol, isopropanol, butanol, nucleic acid, etc. may be used, but is not limited thereto.

The alcohol extract may be distributed and extracted with an organic solvent and water. The organic solvent may be selected from aliphatic hydrocarbons having 1 to 10 carbon atoms, halogenated aliphatic hydrocarbons having 1 to 10 carbon atoms, and esters having 2 to 10 carbon atoms.

The sophoraflavanone G compound of Formula 1 contained in the Kosam extract may be separated by additional chromatography or silica gel column chromatography, and various known methods for isolating a single compound may be applied.

In the present invention, 'Rhein' is a substance of the anthraquinone group obtained from Rhubarb.

The lane may be separated from Rheum undulatum , Rheum plamatum , and Senareticulata ( Cassia reticulate ).

Specifically, the lane of Formula 2 may be separated from rhubarb ( Rheum undulatum ).

In the present invention, 'rhubarb' is a perennial rhizome belonging to the rhizome family, and contains 3.2 to 6.6% of anthraquinone derivatives and 8.2 to 3.6% of tannins in roots and rhizomes (rhizomes). Main ingredients are Lane C ₁₅ H ₈ O ₆ (melting point 321~325℃), Aloemodin C ₁₅ H ₁₀ O ₅ , Emodin C ₁₅ H ₁₀ O ₅ (Francula Emodin), Chrysophanol C ₁₅ H ₁₀ O ₄ (chrysophanoic acid), pasthion C ₁₆ H ₁₂ O ₅ (parietane), etc., and other small amounts of free anthraquinone.

The rhubarb may be extracted using high temperature water of 300 ° C. or higher as a solvent, or may be extracted using alcohol as a solvent. The alcohol may be an aliphatic alcohol having 1 to 6 carbon atoms, and specifically, methanol, ethanol, isopropanol, butanol, nucleic acid, etc. may be used, but is not limited thereto.

The alcohol extract may be distributed and extracted with an organic solvent and water. The organic solvent may be selected from aliphatic hydrocarbons having 1 to 10 carbon atoms, halogenated aliphatic hydrocarbons having 1 to 10 carbon atoms, and esters having 2 to 10 carbon atoms.

The lane of Formula 2 contained in the rhubarb extract may be separated by additional chromatography or silica gel column chromatography, and various known methods for separating a single compound may be applied.

Specifically, the oral bacteria are Streptococcus mutans , S. mutans , Streptococcus sobrinus , S. sobrinus , Actinomyces viscosus, Actinomyces viscosus , A. viscosus , Fusobacterium nucleatum ( Fusobacterium nucleatum , F. nucleatum ) and Porphyromonas gingivalis ( Porphyromonas gingivalis , P. gingivalis ) It may be any one or more uniform selected from the group consisting of.

More specifically, the oral bacteria are from the group consisting of Streptococcus mutans KACC16833, Streptococcus sobrinus KCTC5809, Actinomyces viscosus KCTC9146, Fusobacterium nucleatum KCTC2640 and Porphyromonas gingivalis KCTC5809 It may be one or more selected ones.

The Streptococcus mutans KACC16833, Streptococcus sobrinus KCTC5809, Actinomyces viscosus KCTC9146, Fusobacterium nucleatum KCTC2640, and Porphyromonas gingivalis KCTC5809 are from the Rural Development Administration Agricultural Genetic Resources Information Center (Korean Agricultural Culture Collection, KACC, Jeonju, Korea) and Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (Korean Collection for Type Cultures, KCTC, Daejeon, Korea).

In one embodiment of the present invention, as a result of confirming the minimum inhibitory concentration (MIC) of the composition containing sophoraflavanone G and lane, compared to the case of treatment with sophoraflavanone G or lane alone, the minimum inhibition against oral bacteria It was found that the concentration was low, and it was confirmed that there was sensitivity to all oral bacteria (Tables 1 and 2).

In one embodiment of the present invention, as a result of confirming the growth inhibitory activity by concentration of the composition containing sophoraflabanone G and lane, it was confirmed that the overall growth inhibitory activity effect was excellent regardless of the concentration (Fig. 1 and Table 3 ).

Through the above results, it was confirmed that the antibacterial effect against oral bacteria was remarkably improved by mixing sophoraflabanone G and lane, and, unlike conventional antibiotics, there was no resistance to oral strains.

The composition may further include methanol, ethanol, sodium dodecyl sulfate, Triton X-100, or a mixture thereof.

The composition may further include one or more antimicrobial agents. Specifically, the antibacterial agent may be at least one selected from the group consisting of oxytetracycline, oxacillin, and ampicillin.

Another aspect of the present invention is sophora flavanone G of Formula 1; And it relates to a pharmaceutical composition for the treatment of infections caused by oral bacilli comprising a lane of Formula 2 below.

[Formula 1]

[Formula 2]

Descriptions of 'Soporaflabanone G' and 'Lane' are the same as described above.

In the present invention, 'infectious disease caused by oral bacteria' is Streptococcus mutans ( Streptococcus mutans , S. mutans ), Streptococcus sobrinus ( Streptococcus sobrinus , S. sobrinus ), Actinomyces biscosus ( Actinomyces viscosus , A . _ _ _ _ .

Specifically, the oral bacteria is any one or more homogeneous selected from the group consisting of Streptococcus mutans, Streptococcus sobrinus, Actinomyces viscosus, Husobacterium nucleatum and Porphyromonas gingivalis. can

More specifically, the oral bacteria are from the group consisting of Streptococcus mutans KACC16833, Streptococcus sobrinus KCTC5809, Actinomyces viscosus KCTC9146, Fusobacterium nucleatum KCTC2640 and Porphyromonas gingivalis KCTC5809 It may be one or more selected ones.

In addition, the composition may further include at least one antibacterial agent selected from the group consisting of oxytetracycline, oxacillin, and ampicillin.

In one embodiment of the present invention, as a result of confirming the minimum inhibitory concentration (MIC) and growth inhibitory activity of the composition containing sophoraflavanone G and lane, compared to the case of treatment with sophoraflavanone G or lane alone, oral bacillus It was confirmed that the minimum inhibitory concentration for was low, and the growth inhibitory activity was also excellent regardless of the concentration (Tables 1 to 3 and FIG. 1).

Through the above results, it was confirmed that the antibacterial activity of sophoraflabanone G and lane was effective, and it was confirmed that it could be used for the treatment and prevention of oral diseases caused by oral bacillus infection.

Another aspect of the present invention is sophora flavanone G of Formula 1; And it relates to an antibacterial adjuvant for oral bacteria comprising a lane of Formula 2 below.

[Formula 1]

[Formula 2]

Descriptions of 'Soporaflabanone G' and 'Lane' are the same as described above.

The antibacterial adjuvant may be an antibacterial adjuvant for one or more antibiotics selected from the group consisting of oxytetracycline, oxacillin and ampicillin.

The composition containing Sophoraflavanone G (SPF-G) and Rhein of the present invention is a single compound derived from plants, has low toxicity to the human body and excellent antibacterial activity, thereby preventing diseases caused by oral bacteria. It can be variously used as a composition for prevention, improvement and treatment purposes.

The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be inferred from the detailed description of the present invention or the configuration of the invention described in the claims.

1 is a graph showing the growth curve of P. gingivalis according to the ratio of sophoraflavanone G (SPF-G) and lane (Rhein).

Hereinafter, the embodiments of the present invention will be described in detail with reference to the accompanying drawings, but it is obvious that the present invention is not limited by the following examples.

Example 1. Sophoraflavanone G (Sophoraflavanone) Separation

Sophora flabescens ) The compound of formula 1 contained in the extract was distributed and extracted using water, and separated using a silica gel column chromatography method to obtain a sophora flavanone G compound of formula 1 below.

[Formula 1]

Example 2. Rhein Separation

Rhubarb ( Rheum undulatum ) The compound of formula 2 contained in the extract was distributed and extracted using water, and separated using a silica gel column chromatography method to obtain a lane compound of formula 2 below.

[Formula 2]

Experimental Example 1. Antibacterial activity of sophora flavanone G and rain against oral bacteria

In order to measure the minimum inhibitory concentration (MIC) of Sophoraflavanone SPF-G and Rhein against oral bacteria, a broth microdilution assay was performed.

First, S. mutans , S. sobrinus , A. viscosus , F. nucleatum , P. gingivalis of OD600 = 0.1 were added to a 96-well plate, and then each compound was diluted 2-fold from a maximum of 100 μg / mL. processed. Each plate was incubated at 37º for 24 hours, and then the MIC (Minimum Inhibitory concentration) value was obtained as the minimum concentration that inhibits cell growth. All experiments were repeated three times or more.

Oxytetracycline, oxacillin, and ampicillin were used as positive controls for S. mutans , S. sobrinus , A. viscosus , F. nucleatum , and P. gingivalis . MIC values are shown in Table 1 below.

compound MIC value (μg/mL) S. mutans A. viscosus F. nucleatum P. gingivalis S. sobrinus oxytetracycline
(Oxytetracycline) 50 0.195 0.195 100 1.56 Oxacillin >100 1.56 0.195 1.56 >100 Ampicillin >100 >100 >100 >100 >100 Sophoraflavanone G 3.125 3.125 3.125 >100 3.125 Rhein 100 100 6.25 25 25

g/mL)의 성장을 저해함을 확인하였다. As a result, oxytetracycline was effective against S. mutans (KACC16833: 50 μg/mL), S. sobrinus (KCTC5809: 1.56 μg/mL), A. viscosus (KCTC9146: 0.195 μg/mL), and F. nucleatum (KCTC2640: 0.195 μg/mL), P. gingivalis (KCTC5809: 100

g / mL) was confirmed to inhibit the growth.

Oxacillin inhibited the growth of A. viscosus (KCTC9146: 1.56 μg/mL), F. nucleatum (KCTC2640: 0.195 μg/mL), and P. gingivalis (KACC: 1.56 μg/mL), whereas S. mutans (KACC16833 ), it was confirmed that S. sobrinus (KCTC5809) has resistance.

Ampicillin was resistant to S. mutans (KACC16833), S. sobrinus (KCTC5809), A. viscosus (KCTC9146), F. nucleatum (KCTC2640), and P. gingivalis (KCTC5809).

Lanes are S. mutans (KACC16833: 100 μg/mL), S. sobrinus (KCTC5809: 25 μg/mL), A. viscosus (KCTC9146: 100 μg/mL), F. nucleatum (KCTC2640: 6.25 μg/mL) mL), and P. gingivalis (KCTC5809: 25 μg/mL), but the effect was shown at a relatively high concentration.

Sophoraflavanone G is S. mutans (KACC16833: 3.125 μg/mL), S. sobrinus (KCTC5809: 3.125 μg/mL), A. viscosus (KCTC9146: 3.125 μg/mL), F. nucleatum (KCTC2640: 3.125 μg /mL), whereas it was confirmed that the growth of P. gingivalis (KCTC5809) was not inhibited.

Through the above results, it was confirmed that the antibacterial activity of sophoraflabanone G was relatively better than that of the lane, but that the lane had a stronger antibacterial effect against P. gingivalis than conventional antibiotics. However, compared to the antibacterial effect of existing antibiotics, the antibacterial effect of sophoraflavanone G and lane was not particularly remarkable.

Experimental Example 2. Antibacterial activity of sophora flavanone G and lane mixture against oral bacteria

An experiment was performed to confirm the synergistic effect of antibacterial activity against oral bacteria by mixing sophoraflabanone G and lane.

To confirm the effect of sophoraflabanone G and lane mixture on the growth of S. mutans , S. sobrinus , A. viscosus , F. nucleatum , and P. gingivalis , sophoraflabanone G and lane , sophoraflavanone G and ampicillin (AMP), sophoraflavanone G and oxacillin (OXC), sophoraflabanone G and oxytetracycline (OXY), respectively, while growing bacteria at 37 ° C. Growth over time was observed.

FICI (Fractional inhibitory concentration index) is the sum of FIC (Fractional inhibitory concentration) values in the most effective combination, and is most commonly used when interpreting study results of antibiotic combination effects. If the FICI is less than 0.5, it is judged to be synergistic, if it is more than 2.0, it is antagonistic, and if the value is in between, it is judged to be additive. Equation 1 below is a calculation method of FIC.

Here, (A) refers to the MIC when a drug to be used in combination with drug A is used in combination, and MIC _A refers to the MIC when drug A is used alone. Equation 2 below is a calculation method of FICI.

The experimental results are shown in Table 2 below.

Strain compound MIC [μg/mL] FICI Sophoraflavanone G
single lane
single Sophoraflavanone G
+
lane lane
+
Sophoraflavanone G S. mutans Sophoraflavanone G 1.56 100 0.195 6.25 0.2 A. viscosus Sophoraflavanone G 3.125 100 0.0976 6.25 0.1 F. nucleatum Sophoraflavanone G 1.56 6.25 0.39 0.39 0.3 P. gingivalis Sophoraflavanone G >100 25 0.78 1.56 - S. sobrinus Sophoraflavanone G 3.125 25 0.39 0.39 0.2

* Sophoraflabanone G + lane: MIC value of sophoraflabanone G and lane treatment, lane + sophoraflabanone G: MIC value of lane treatment sophoraflabanone G and lane

As a result, it was confirmed that the mixture containing both sophoraflabanone G and lane had an overall excellent antibacterial effect against oral strains without resistance. In particular, in Table 1, sophora flavanone G was resistant to P. gingivalis , and the lane was shown to have resistance to S. mutans and A. viscosus , but in the mixture, for all three strains The antibacterial activity was excellent.

On the other hand, some oral bacteria are resistant to existing antibiotics, and specifically, all of the five oral bacteria are resistant to ampicillin, and S. mutans and S. sobrinus are also resistant to oxacillin. Confirmed. In addition, it was confirmed that P. gingivalis has resistance to sophoraflavanone G and ampicillin.

The above results suggest that a composition having a synergistic effect on the antibacterial activity of buccal bacteria and superior antibacterial effect compared to conventional antibiotics can be provided by mixing sophoraflabanone G and lane.

Experimental Example 3. Antibacterial activity against oral bacteria of sophora flavanone G and lane mixtures by concentration

To confirm the antibacterial activity against S. mutans , S. sobrinus , A. viscosus , F. nucleatum , and P. gingivalis by concentration of sophora flavanone G and lane mixture, disc diffusion test using solid medium assay) was performed.

Specifically, the growth inhibitory effect of S. mutans , A. viscosus , F. nucleatum , P. gingivalis or S. sobrinus was observed according to the concentration ratio of sophoraflabanone G and lanes, and cell growth caused by growth inhibition was not observed. It is indicated by measuring the size of the area not covered. The experimental results are shown in Table 3 below.

compound Inhibition zone (nm) S. mutans A. viscosus F. nucleatum P. gingivalis S. sobrinus oxytetracycline 2.0 2.3 2.8 1.0 2.3 Sophoraflavanone G (SPF-G) 0.9 0.9 0.8 0.8 1.0 Lane (RH) 1.0 0.9 1.2 0.8 1.2 RH (25 μg/mL)+SPF-G (0.78 μg/mL) 1.4 1.3 1.5 2.2 1.3 RH (25 μg/mL)+SPF-G (0.39 μg/mL) 1.0 1.0 1.4 1.9 1.0 RH (12.5 μg/mL) + SPF-G (1.56 μg/mL) 1.6 1.0 1.2 1.8 1.0 RH (12.5 μg/mL)+S PF-G (0.78 μg/mL) 1.5 1.0 1.2 1.7 1.0 RH (12.5 μg/mL)+S PF-G (0.39 μg/mL) 1.0 1.0 1.0 1.6 1.0 RH (6.25 μg/mL)+S PF-G (0.78 μg/mL) - 0.8 1.2 1.8 0.8

As a result, in the case of oxytetracycline, S. mutans (KACC16833: 2.0 mm), S. sobrinus (KCTC5809: 2.3 mm), A. viscosus (KCTC9146: 2.3 mm), F. nucleatum (KCTC2640: 2.8 mm), P. gingivalis (KCTC5352: 1 mm).

For sophoraflavanone G, S. mutans (KACC16833: 0.9 mm), S. sobrinus (KCTC5809: 1 mm), A. viscosus (KCTC9146: 0.9 mm), F. nucleatum (KCTC2640: 0.8 mm), P. gingivalis (KCTC5352: 0.8 mm).

For lanes, S. mutans (KACC16833: 1 mm), S. sobrinus (KCTC5809: 1.2 mm), A. viscosus (KCTC9146: 0.9 mm), F. nucleatum (KCTC2640: 1.2 mm), P. gingivalis (KCTC5352: 0.8 mm) was confirmed to inhibit the growth.

For RH (25 μg/mL)+SPF-G (0.78 μg/mL), S. mutans (KACC16833: 1.4 mm), S. sobrinus (KCTC5809: 1.3 mm), A. viscosus (KCTC9146: 1.3 mm), F It was confirmed that it inhibited the growth of nucleatum (KCTC2640: 1.5 mm) and P. gingivalis (KCTC5352: 2.2 mm).

In the case of RH (25 μg/mL)+SPF-G (0.39 μg/mL), S. mutans (KACC16833: 1 mm), S. sobrinus (KCTC5809: 1 mm), A. viscosus (KCTC9146: 1 mm), It was confirmed that it inhibited the growth of F. nucleatum (KCTC2640: 1.4 mm) and P. gingivalis (KCTC5352: 1.9 mm).

In the case of RH (12.5 μg/mL)+SPF-G (1.56 μg/mL), S. mutans (KACC16833: 1.6 mm), S. sobrinus (KCTC5809: 1 mm), A. viscosus (KCTC9146: 1 mm), It was confirmed that it inhibited the growth of F. nucleatum (KCTC2640: 1.2 mm) and P. gingivali s (KCTC5352: 1.8 mm).

In the case of RH (12.5 μg/mL)+SPF-G (0.78 μg/mL), S. mutans (KACC16833: 1.5 mm), S. sobrinus (KCTC5809: 1 mm), A. viscosus (KCTC9146: 1 mm), It was confirmed that it inhibited the growth of F. nucleatum (KCTC2640: 1.2 mm) and P. gingivalis (KCTC5352: 1.7 mm).

In the case of RH (12.5 μg/mL)+SPF-G (0.39 μg/mL), S. mutans (KACC16833: 1 mm), S. sobrinus (KCTC5809: 1 mm), A. viscosus (KCTC9146: 1 mm), It was confirmed that it inhibited the growth of F. nucleatum (KCTC2640: 1 mm) and P. gingivalis (KCTC5352: 1.6 mm).

In the case of RH (6.25 μg/mL)+SPF-G (0.78 μg/mL), S. sobrinus (KCTC5809: 0.8 mm), A. viscosus (KCTC9146: 0.8 mm), F. nucleatum (KCTC2640: 1.2 mm), It was confirmed that the growth of P. gingivalis (KCTC5352: 1.8 mm) was inhibited, and the growth of S. mutans (KACC16833) was not inhibited.

In the case of RH (6.25 μg/mL)+SPF-G (0.39 μg/mL), S. sobrinus (KCTC5809: 0.8 mm), A. viscosus (KCTC9146: 0.8 mm), F. nucleatum (KCTC2640: 1.2 mm), It was confirmed that the growth of P. gingivalis (KCTC5352: 1.8 mm) was inhibited, and the growth of S. mutans (KACC16833) was not inhibited.

Also, oxytetracycline in the case of P. gingivalis . It was confirmed that the treatment according to the concentration ratio of RH + SPF-G showed a strong antibacterial effect against P. gingivalis than the treatment of sophoraflabanone G and lane alone.

Experimental Example 4. Oral bacteria growth inhibitory activity according to the concentration of sophora flavanone G and lane mixture

In order to confirm the effect on the growth of P. gingivalis according to the concentration ratio of sophoraflabanone G and lanes confirmed to have the antibacterial action, OD600 = 0.1 Sophoraflabanone G and lanes were respectively ratioed to P. gingivalis After treatment with each mixture, growth was observed over time while growing bacteria at 37 ° C (Fig. 1).

As a result, it was confirmed that the growth of P. gingivalis was inhibited according to the ratio when sophoraflabanone G and lanes were treated at different ratios. That is, it was confirmed that the growth of P. gingivalis was inhibited according to the ratio of sophoraflabanone G and lane.

Through the above results, it was confirmed that both the sophoraflabanone G and the lane mixtures had excellent antibacterial activity against oral bacteria at various concentrations.

The above description of the present invention is for illustrative purposes, and those skilled in the art can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.

The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included in the scope of the present invention.

Claims (11)

Sophoraflavanon G of Formula 1 below; and
In the antibacterial composition for oral bacteria containing the rain (Rhein) of the formula (2),
Wherein the sophora flavanone G and Lane are mixed in a weight ratio of 1:8 to 1:64.
[Formula 1]

[Formula 2]

According to claim 1,
Sophora flavanone G of Formula 1 is isolated from Sophora flavescens , an antimicrobial composition. According to claim 1,
The lane of Formula 2 is rhubarb ( Rheum undulatum ) It will be separated from, antibacterial composition. According to claim 1,
The oral bacteria are Streptococcus mutans , S. mutans , Streptococcus sobrinus , S. sobrinus , Actinomyces viscosus , Husobacter Leeum nucleatum ( Fusobacterium nucleatum , F. nucleatum ) And Porphyromonas gingivalis ( Porphyromonas gingivalis , P. gingivalis ) Which one or more bacteria selected from the group consisting of, antimicrobial composition. According to claim 1,
The composition is an antimicrobial composition further comprising methanol, ethanol, sodium dodecyl sulfate, Triton (Triton) X-100 or a mixture thereof. According to claim 1,
The composition is an antimicrobial composition further comprising one or more antimicrobial agents. According to claim 6,
The antimicrobial agent is any one or more selected from the group consisting of oxytetracycline, oxacillin and ampicillin, antimicrobial composition. Sophora flavanone G of Formula 1; and
In the pharmaceutical composition for the treatment of infections caused by oral bacteria comprising the lane of formula (2),
A pharmaceutical composition wherein the sophoraflavanone G and Lane are mixed in a weight ratio of 1:8 to 1:64.
[Formula 1]

[Formula 2]

According to claim 8,
The oral bacteria are Streptococcus mutans ( S. mutans ), Streptococcus sobrinus ( Streptococcus sobrinus , S. sobrinus ), Actinomyces viscosus ( Actinomyces viscosus , A. viscosus ), Husobacter Leeum nucleatum ( Fusobacterium nucleatum , F. nucleatum ) and Porphyromonas gingivalis ( Porphyromonas gingivalis , P. gingivalis ) Any one or more bacteria selected from the group consisting of, a pharmaceutical composition. According to claim 8,
Wherein the composition further comprises at least one antimicrobial agent selected from the group consisting of oxytetracycline, oxacillin and ampicillin. Sophora flavanone G of Formula 1; and
In the antibacterial adjuvant for oral bacteria comprising the lane of formula (2),
An antibacterial adjuvant wherein the sophoraflabanone G and Lane are mixed in a weight ratio of 1:8 to 1:64.
[Formula 1]

[Formula 2]

Images